Oral Lichen Planus Successfully Treated With Upadacitinib
Kristin Slater, Katelyn Halash, Francisca Kartono
Abstract
With the rise of Janus kinase (JAK) and Signal Transducer and Activator of Transcription (STAT) inhibitor use in dermatologic conditions, there has been increasing hope in treating extensive and difficult-to-treat inflammatory cutaneous conditions. Today we report a case of oral lichen planus successfully treated with an oral JAK1 inhibitor, upadacitinib. This case had been unresponsive by several standard methods but responded with 70% improvement within 1 month when treated with upadacitinib. J Drugs Dermatol. 2024;23(4):7859. doi:10.36849/JDD.7859e  .
Topics & Concepts
MedicineJanus kinaseDermatologystatOral lichen planusSTAT proteinPharmacologyInternal medicineReceptorSignal transductionSTAT3BiochemistryChemistryOral Health Pathology and TreatmentAutoimmune Bullous Skin DiseasesInterstitial Lung Diseases and Idiopathic Pulmonary Fibrosis